|
|
Vaccine Detail
|
Autologous Pluripotent ALDHbr Stem Cells ALD-451 |
| Vaccine Information |
- Vaccine Name: Autologous Pluripotent ALDHbr Stem Cells ALD-451
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007312
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- ALDH1A1
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- ALDH2
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: β-like cells can be derived from autologous pluripotent stem cells (Millman and Pagliuca, 2017).
- Description: A specific population of autologous, pluripotent bone marrow derived cells that express high levels of the cytosolic enzyme aldehyde dehydrogenase (ALDH) with potential protective and neuro-cognition improving activity. Expression of high levels of ALDH is an indicator of the biological activity in heterogenous early stage stem cells. Upon intravenous administration, these ALDH bright cells may protect normal cells and may repair damaged cells. These cells may also protect brain cells from damage and may improve neurocognition. (NCIT_C78466).
This vaccine has been used in trials involving malignant glioma. https://discovery.lifemapsc.com/regenerative-medicine/cell-therapy-applications/brain-ald451-bone-marrow-derived-cells-for-malignant-glioma, NCT01639612
|
| Host Response |
|
|
| References |
Millman and Pagliuca, 2017: Millman JR, Pagliuca FW. Autologous Pluripotent Stem Cell-Derived β-Like Cells for Diabetes Cellular Therapy. Diabetes. 2017; 66(5); 1111-1120. [PubMed: 28507211].
NCIT_C78466: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C78466]
|
|
